{"version":"1.0","type":"card","id":"1da9674e-16f0-47ef-bbb8-6db9406cdcc4","url":"https://stacklist.com/card/1da9674e-16f0-47ef-bbb8-6db9406cdcc4","title":"Psychedelic-assisted therapy: An overview for the internist","source_url":"https://www.ccjm.org/content/92/3/171","note":"Preliminary evidence suggests that psychedelic-assisted therapy—the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin—may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid diethylamide designated breakthrough therapies by the US Food and Drug Administration (FDA).","image":{"url":"https://ucarecdn.com/19f7884b-4749-4bc8-898c-6b0f127c70ff/","alt":"Psychedelic-assisted therapy: An overview for the internist","width":32,"height":32},"stack":{"id":"3ec64f10-f7d6-4a20-a3c9-499572b61636","title":"Psychedelic Therapy & Integration","url":"https://stacklist.com/c/wellness/stack/3ec64f10-f7d6-4a20-a3c9-499572b61636"},"created_at":"2026-08-23T10:16:43.064Z","updated_at":null,"aco":{"summary":"Psychedelic-assisted therapy, combining psychotherapy with compounds such as MDMA, psilocybin, and LSD, shows preliminary efficacy for depression, PTSD, and substance use disorders, with potential for durable effects after a single session. The article reviews therapeutic applications, safety profiles, pharmacologic mechanisms, and the current FDA regulatory landscape, urging internists to prepare for possible clinical integration.","tags":["psychedelic-assisted-therapy","psilocybin","mdma","psychiatry","clinical-trials","substance-use-disorders","ptsd"],"key_entities":[{"name":"Psychedelic-Assisted Therapy","type":"concept","confidence":0.99},{"name":"Psilocybin","type":"technology","confidence":0.97},{"name":"MDMA","type":"technology","confidence":0.97},{"name":"Lysergic Acid Diethylamide (LSD)","type":"technology","confidence":0.9},{"name":"US Food and Drug Administration (FDA)","type":"organization","confidence":0.98},{"name":"Posttraumatic Stress Disorder (PTSD)","type":"concept","confidence":0.93},{"name":"Serotonin 2A Receptor Agonism","type":"concept","confidence":0.85},{"name":"Set and Setting","type":"concept","confidence":0.8},{"name":"Ketamine","type":"technology","confidence":0.75}],"classification":"reference","language":"en","confidence":0.85,"provenance":{"model":"claude-opus-4-6","tool":"@stacklist/mcp-server@2.0.0","confidence":0.85,"timestamp":"2026-08-23T10:17:00.854Z"},"token_counts":{"approximate":11491,"cl100k":10578},"content_hash":"sha256:8a4ac3060081048a30b83af64ae0e815681b7794706f38b92c82e7538ceff0d8","acp_version":"0.2","body_available":true,"body_tokens":11491,"visibility":"public","agent_accessible":true,"status":"final"},"_links":{"self":"/api/public/card/1da9674e-16f0-47ef-bbb8-6db9406cdcc4.json","html":"https://stacklist.com/card/1da9674e-16f0-47ef-bbb8-6db9406cdcc4","md":"/api/public/card/1da9674e-16f0-47ef-bbb8-6db9406cdcc4.md","stack_json":"/api/public/stack/3ec64f10-f7d6-4a20-a3c9-499572b61636.json"}}